Skip Navigation LinksHome > July 31, 2014 - Volume 28 - Issue 12 > Safety and immunogenicity of the M72/AS01 candidate tubercul...
doi: 10.1097/QAD.0000000000000343
Clinical Science

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial

Thacher, Eleonora G.a,*; Cavassini, Matthiasb,*; Audran, Réginea; Thierry, Anne-Christinea; Bollaerts, Annec; Cohen, Joec; Demoitié, Marie-Angec; Ejigu, Dawitc; Mettens, Pascalc; Moris, Philippec; Ofori-Anyinam, Opokuac,†; Spertini, Françoisa,†

Supplemental Author Material


In this paper by Eleonora et al. [1], there is an error in the legend of the Y-axis of Fig 4a: M72-specific CD4+ T-cell responses following vaccination with M72/A S01.

The legend of Y-axis in Fig 4a incorrectly refers to ‘M72-specific CD4+ T cells expressing at least 3 markers (%)’. The correct Y-axis legend should read ‘M72-specific CD4+ T cells expressing at least 2 markers (%)’.

Please see the corrected Fig 4a here.

AIDS. 29(7):865, April 24, 2015.

Collapse Box


Objective: Tuberculosis (TB) is highly prevalent among HIV-infected people, including those receiving combination antiretroviral therapy (cART), necessitating a well tolerated and efficacious TB vaccine for these populations. We evaluated the safety and immunogenicity of the candidate TB vaccine M72/AS01 in adults with well controlled HIV infection on cART.

Design: A randomized, observer-blind, controlled trial (NCT00707967).

Methods: HIV-infected adults on cART in Switzerland were randomized 3 : 1 : 1 to receive two doses, 1 month apart, of M72/AS01, AS01 or 0.9% physiological saline (N = 22, N = 8 and N = 7, respectively) and were followed up to 6 months postdose 2 (D210). Individuals with CD4+ cell counts below 200 cells/μl were excluded. Adverse events (AEs) including HIV-specific and laboratory safety parameters were recorded. Cell-mediated (ICS) and humoral (ELISA) responses were evaluated before vaccination, 1 month after each dose (D30, D60) and D210.

Results: Thirty-seven individuals [interquartile range (IQR) CD4+ cell counts at screening: 438–872 cells/μl; undetectable HIV-1 viremia] were enrolled; 73% of individuals reported previous BCG vaccination, 97.3% tested negative for the QuantiFERON-TB assay. For M72/AS01 recipients, no vaccine-related serious AEs or cART-regimen adjustments were recorded, and there were no clinically relevant effects on laboratory safety parameters, HIV-1 viral loads or CD4+ cell counts. M72/AS01 was immunogenic, inducing persistent and polyfunctional M72-specific CD4+ T-cell responses [medians 0.70% (IQR 0.37–1.07) at D60] and 0.42% (0.24–0.61) at D210, predominantly CD40L+IL-2+TNF-α+, CD40L+IL-2+ and CD40L+IL-2+TNF-α+IFN-γ+]. All M72/AS01 vaccines were seropositive for anti-M72 IgG after second vaccination until study end.

Conclusion: M72/AS01 was clinically well tolerated and immunogenic in this population, supporting further clinical evaluation in HIV-infected individuals in TB-endemic settings.

© 2014 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.